BioNTech SE Sponsored ADR BNTX
98.52
(0.74)
(0.75%)
as of 25 Sep
- Market cap
- $24.9B
- P/E
- 0.0×
Follow BNTX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (9.53%) | (7.03%) | (6.01%) | (2.99%) |
+8 more TTM periods Free account |
|
| (8.24%) | (6.26%) | (5.22%) | (2.57%) | ||
ROIC |
(38.39%) | (22.28%) | (19.03%) | (13.11%) | |
Return on Tangible Assets |
(11.87%) | (8.44%) | (7.53%) | (3.72%) | |
Average Days of Receivables |
33.00 | 80.73 | 124.23 | 93.74 | |
Free Cash Flow per Share |
1.98 | 2.22 | (1.35) | (5.15) | |
Free Cash Flow |
500.72 | 563.49 | (326.41) | (1,231.70) | |
Capital Expenditures |
(257.85) | (282.16) | (842.33) | (889.87) | |
Piotroski F-Score |
2.00 | 3.00 | 4.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
1.99% | 2.15% | 1.33% | (0.88%) | |
Accounts Receivable Turnover |
3.17 | 3.59 | 2.37 | 3.17 | |
Accounts Payable Turnover |
1.13 | 1.42 | 1.36 | 0.93 | |
Inventory Turnover |
3.95 | 3.70 | 3.36 | 2.04 | |
Average Days of Payables |
367.17 | 277.61 | 304.20 | 280.17 | |
Days of Inventory on Hand |
57.12 | 61.47 | 62.96 | 158.17 | |
Tax Rate |
0.03 | 0.06 | 0.08 | 0.10 | |
Research and Development Expense of Revenue |
84.20% | 77.67% | 73.34% | 69.28% | |
Selling, General and Administrative Expense of Revenue |
27.49% | 23.68% | 21.76% | 16.92% | |
Share Based Compensation of Revenue |
2.66% | 3.02% | 2.82% | 2.50% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
(0.38) | (0.58) | (0.40) | 0.54 | |
Depreciation/Fixed assets |
0.65 | 0.41 | 0.35 | 0.36 | |
Capex/Depreciation |
(0.33) | (0.53) | (1.94) | (2.06) | |
Revenue per Share |
11.92 | 12.61 | 13.43 | 14.76 | |
Operating CF per Share |
2.99 | 3.34 | 2.13 | (1.43) | |
Capex per Share |
(1.02) | (1.11) | (3.48) | (3.72) | |
Capex to Sales |
0.09 | 0.09 | 0.26 | 0.25 | |
Net Profit Margin |
(65.75%) | (46.04%) | (39.59%) | (18.02%) |
Columns are period end dates